Cerebain Biotech Presents Corporate Update on Its War against Alzheimer’s and Dementia

DALLAS--()--Cerebain Biotech (OTCQB: CBBT) today announced that the executive team of Cerebain Biotech Corp. is very pleased to provide an update on the progress made over the last year and an outlook of 2016.

  • Our research suggests we have three options for implantable devices with a bias towards having them as non-invasive as possible. The options are comprised of two electro-stim types that have a multitude of variable test parameters that can be changed and modified externally as the testing facility conducts clinical trials on each patient. Manufacturing should begin next year.
  • We recently were invited and participated in an event hosted by the Polish National Center for Research and Development. The workshop centered on recommended improvements in practice and process to increase innovative advances in biomedicine and improved health care through IT applications. Representing the Company was CEO Eric Clemons and Governor Scott McCallum.
  • Cerebain has been identified as one of the joint projects in innovation that have potential for collaboration between Poland organizations and the U.S. These discussions took place in meetings held in Warsaw on October 7.
  • The following summarizes Cerebain’s strategic plan for maximizing shareholder value over the coming months:
    • Strategically prepare for the commencement of our clinical trial studies in Q1 or Q2 2016 including necessary filings and strategic partnerships.
    • Allocate resources to administer grant applications for further research and testing of Cerebain’s existing technology.
    • Design a surgical manual to be used by doctors and clinicians for the purpose of implanting our medical device.
    • Provide additional administrative and financial support to our scientists to leverage their time to advance our technologies in or near trials.

Eric Clemons, President of Cerebain, stated, “We would like to offer a heartfelt thank you to each and every shareholder: past, current, and future for your unwavering support of our company and for also taking the time to read this important shareholder update. We are extremely excited to continue to move forward with our development plan and to do everything in our power to add shareholder value and eradicate Alzheimer’s disease.”

About Cerebain Biotech Corp.

Cerebain Biotech (OTCQB: CBBT) is a development-stage medical device company focused on the creation and clinical development of a minimally invasive implantable device and a synthetic drug solution. The device leverages the clinically observable, positive impact that omentum stimulation has on cognitive function as related to dementias, and in particular, Alzheimer’s disease. The corporate vision is based on these positive clinical observations.

Forward-Looking Statements

This news release contains certain "forward-looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. The forward-looking statements are also identified through the use of words "believe," enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict" "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company's reports filed with OTC Markets. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved.

Contacts

Cerebain Biotech Corp.
Mr. Alan Klitenic, 888-430-2221
info@cerebain.com

Cerebain Biotech